Strong Performance Yet... MedTech Stock Loses 6 Trillion Won in a Day

Boston Scientific Corporation (BSX) plunged 5.51% on April 24 in New York trading, closing at $62.07. In a single day, roughly $4.8 billion in market capitalization—about ₩6 trillion—vanished, swiftly erasing the gains from its recent earnings-driven rally.

Despite posting strong first-quarter results, the company cut its full-year 2026 guidance, and concerns over slowing growth in its electrophysiology business—combined with disappointing guidance issued earlier this year and an ongoing securities class action—appear to have dampened investor sentiment.

On April 22, Boston Scientific reported first-quarter revenue of $5.23 billion and adjusted EPS of $0.80, slightly beating both market expectations and its own forecasts. Nevertheless, it lowered its full-year revenue and earnings growth targets, signaling a “growth reset.”

Following the earnings release, Barclays trimmed its price target on BSX from $124 to $100, and other major brokerages followed suit. On April 24, organizers of a securities class action alleging overly optimistic 2025 growth projections in the electrophysiology segment announced a May 4 deadline for lead-plaintiff applications, highlighting mounting legal risks.

Headquartered in Marlborough, Massachusetts, Boston Scientific is a global medical-device leader known for cardiovascular stents, arrhythmia-treatment catheters, and minimally invasive systems such as the Watchman left-atrial appendage closure device.

Since Michael Mahoney became CEO, the company has aggressively invested in high-growth areas—pulsed-field ablation for arrhythmias, neuromodulation, and urology and pain-management technologies. The coming quarters will be closely watched to see whether this “growth reset” proves temporary.